Skip to main content

September 2022

 

 

academics

 

Clinical research courses

Vacancy for MSc, B.Pharm in Packing, Production at Ind-Swift Limited

Ind-Swift Limited - Jawaharpur, Derabassi is the Ace unit of Ind-Swift Limited, was created in the year 2005 with an aim to globalize the Ind-Swift brand for finished dosage forms. We are a 100% Export Oriented Unit dealing in regulated markets having approval like MHRA, TGA & GLC etc.

OPEN POSITIONS for Formulation Site

Pfizer and Moderna receives FDA approval for Omicron targeting booster vaccine

Pfizer Inc. and BioNTech announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent for individuals ages 12 years and older.

And on the same day,  Moderna, Inc. has also received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Omicron-targeting bivalent COVID-19 booster vaccine.

Outdated cancer drug in combination found effective against lung cancer

An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a study in mice from researchers at Washington University School of Medicine in St. Louis, Grenoble Alpes University in Grenoble, France, and The University of Texas MD Anderson Cancer Center in Houston.

Anti Malarial medicine has potential to kill MDR Bacteria

University researchers have found a naturally occurring compound, known as hydroquinine, has bacterial killing activity against several microorganisms.

Antimicrobial resistance has become one of the greatest threats to public health globally. It occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making it difficult to treat infections. Because of this, there is a pressing need for the development of new antimicrobial drugs to combat infections.

Xenpozyme developed by Sanofi wins FDA approval

The U.S. Food and Drug Administration has approved Xenpozyme for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency in adult and pediatric patients.

Xenpozyme is the first therapy indicated specifically for the treatment of ASMD (acid sphingomyelinase deficiency), and is currently the only approved treatment for this disease.

No more free COVID-19 vaccines in USA, foreseeing full commercialization

From 2023, there will be no free COVID-19 vaccines for Americans. The US federal government may opt for full commercialization of COVID-19 vaccines and other oral antiviral medicines.

The US federal government has played the central coordinating role in buying, distributing, and ensuring equitable access to COVID-19 vaccines, therapeutics, and tests.

Clinical Research, Quality Assurance Job Openings at Synapse Labs | M.Pharm, B.Pharm apply

Synapse Labs is a Contract Research Organization (CRO) which offers a range of services to the Pharmaceutical and Biotechnology industry. We are dedicated to quality service, with focus on reducing time and cost, We are achieving this by understanding client requirement and working close with them to match their timeline.

Post : Clinical Research / Quality Assurance Job Openings - Pune

Serum Institute of India inks with Aspen to sell four vaccines in Africa

Aspen Pharmacare has concluded a ten-year agreement with Serum Institute of India, the world’s largest vaccine producer, for Aspen SA operations to manufacture, market and distribute four Aspen-branded routine vaccines in Africa, excluding certain markets due to the Serum Institute having grated prior rights to third parties.

Postdoctoral Position at University of Basel

The University of Basel is a university in Basel, Switzerland. Founded on 4 April 1460, it is Switzerland's oldest university and among the world's oldest surviving universities. The university is traditionally counted among the leading institutions of higher learning in the country.

Post : Postdoctoral Position in Peptide Chemistry and Drug Design

USFDA issues Form 483s to three sites of Biocon

U.S. Food and Drug Administration (USFDA) issues Form 483s to three sites of Biocon Biologics at India and Malaysia. USFDA issues 11 observations each for the two sites in Bengaluru and 6 observations for the Malaysia site.

USFDA conducted three on-site inspections of Biocon Biologics seven manufacturing facilities spanning two sites in Bengaluru, India and one at Johor, Malaysia. These inspections started with the Bengaluru site on August 11, 2022 and concluded with the Malaysia site on August 30, 2022.